phase II clinical study
In the TRUST-II trial, 85 percent of ROS1 TKI-naïve NSCLC patients and 62 percent of TKI-pretreated patients responded to the next-generation ROS1 inhibitor.
PolTreg T-Regulatory Cell Therapy Shows Clinical Remission in Type 1 Diabetes for up to 12 Years
The company is now seeking partnership funding to launch a pivotal Phase II/III study of the autologous T-regulatory cell therapy.
Promising 12-Month Data on Atsena's LCA1 Gene Therapy Bolsters Case of Pivotal Trial
The latest safety and efficacy Phase I/II data on ATSN-101 support moving the gene therapy into a randomized Phase III trial.
Researchers Aim to Confirm Benefits of Non-Hormonal Therapy for Certain Prostate Cancer Patients
Premium
Prostate cancer patients with BRCA2 and other homologous recombination repair mutations fared better on Lynparza than those without genomic alterations.
Arsenal Biosciences Raises $325M in Series C Financing Round
The firm will use the funds to continue developing its pipeline of CAR T-cell therapies, scale up manufacturing capabilities, and explore novel T-cell therapies.
Aug 27, 2024
Jul 29, 2024
Jul 24, 2024
Jul 24, 2024